Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use

Ibrutinib‐based combination therapy with high‐dose methotrexate (HD‐MTX) has recently shown clinical activity against relapse/refractory (R/R) primary central nervous system lymphoma (PCNSL). Herein, we report our real‐world experience of treating 11 newly diagnosed PCNSL patients with the ibrutinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Feili, Pang, Diwen, Guo, Hanguo, Ou, Qiuxiang, Wu, Xue, Jiang, Xinmiao, Wei, Xiaojuan, Liu, Sichu, Huang, Ling, Liang, Zhanli, Zhou, Dong, Li, Wenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Cancer Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666749/
https://www.ncbi.nlm.nih.gov/pubmed/33068336
http://dx.doi.org/10.1002/cam4.3499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666749/
https://www.ncbi.nlm.nih.gov/pubmed/33068336
http://dx.doi.org/10.1002/cam4.3499

Ejemplares similares